Brain-targeted drug delivery - nanovesicles directed to specific brain cells by brain-targeting ligands
Authors:
Open Access
- 17 May 2024
- journal article
- review article
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 22 (1) , 1-26
Abstract
Neurodegenerative diseases are characterized by extensive loss of function or death of brain cells, hampering the life quality of patients. Brain-targeted drug delivery is challenging, with a low success rate this far. Therefore, the application of targeting ligands in drug vehicles, such as lipid-based and polymeric nanoparticles, holds the promise to overcome the blood-brain barrier (BBB) and direct therapies to the brain, in addition to protect their cargo from degradation and metabolization. In this review, we discuss the barriers to brain delivery and the different types of brain-targeting ligands currently in use in brain-targeted nanoparticles, such as peptides, proteins, aptamers, small molecules, and antibodies. Moreover, we present a detailed review of the different targeting ligands used to direct nanoparticles to specific brain cells, like neurons (C4-3 aptamer, neurotensin, Tet-1, RVG, and IKRG peptides), astrocytes (Aquaporin-4, D4, and Bradykinin B2 antibodies), oligodendrocytes (NG-2 antibody and the biotinylated DNA aptamer conjugated to a streptavidin core Myaptavin-3064), microglia (CD11b antibody), neural stem cells (QTRFLLH, VPTQSSG, and NFL-TBS.40–63 peptides), and to endothelial cells of the BBB (transferrin and insulin proteins, and choline). Reports demonstrated enhanced brain-targeted delivery with improved transport to the specific cell type targeted with the conjugation of these ligands to nanoparticles. Hence, this strategy allows the implementation of high-precision medicine, with reduced side effects or unwanted therapy clearance from the body. Nevertheless, the accumulation of some of these nanoparticles in peripheral organs has been reported indicating that there are still factors to be improved to achieve higher levels of brain targeting. This review is a collection of studies exploring targeting ligands for the delivery of nanoparticles to the brain and we highlight the advantages and limitations of this type of approach in precision therapies.Keywords
Funding Information
- European Regional Development Fund (ERDF) through the Centro 2020 Regional Operational Programme (under BrainHealth2020 projects (CENTRO-01-0145-FEDER-000008), through the COMPETE 2020 - Operational Programme for Competitiveness and Internationalization and Portuguese national funds via FCT – Fundação para a Ciência e a Tecnologia, under projects - UIDB/04539/2020 and UIDP/04539/2020, POCI-01-0145-FEDER-030737 (NeuroStemForMJD, PTDC/BTM-ORG/30737/2017), CEECIND/04242/2017, and PhD Scholarship, under BrainHealth2020 projects (CENTRO-01-0145-FEDER-000008), through the COMPETE 2020 - Operational Programme for Competitiveness and Internationalization and Portuguese national funds via FCT – Fundação para a Ciência e a Tecnologia, under projects - UIDB/04539/2020 and UIDP/04539/2020, POCI-01-0145-FEDER-030737 (NeuroStemForMJD, PTDC/BTM-ORG/30737/2017), CEECIND/04242/2017, and PhD Scholarship)
This publication has 296 references indexed in Scilit:
- From Adsorption to Covalent Bonding: Apolipoprotein E Functionalization of Polymeric Nanoparticles for Drug Delivery Across the Blood–Brain BarrierAdvanced Therapeutics, 2020
- Large‐Scale Synthesis and Medical Applications of Uniform‐Sized Metal Oxide NanoparticlesAdvanced Materials, 2018
- Ceria–Zirconia Nanoparticles as an Enhanced Multi‐Antioxidant for Sepsis TreatmentAngewandte Chemie International Edition, 2017
- Ultrasound‐Triggered Destruction of Folate‐Functionalized Mesoporous Silica Nanoparticle‐Loaded Microbubble for Targeted Tumor TherapyAdvanced Healthcare Materials, 2017
- Rabies Virus‐Inspired Silica‐Coated Gold Nanorods as a Photothermal Therapeutic Platform for Treating Brain TumorsAdvanced Materials, 2017
- Neurotensin‐Conjugated Reduced Graphene Oxide with Multi‐Stage Near‐Infrared‐Triggered Synergic Targeted Neuron Gene Transfection In Vitro and In Vivo for Neurodegenerative Disease TherapyAdvanced Healthcare Materials, 2016
- New p32/gC1qR Ligands for Targeted Tumor Drug DeliveryChemBioChem, 2016
- Choline‐Derivate‐Modified Nanoparticles for Brain‐Targeting Gene DeliveryAdvanced Materials, 2011
- Co‐encapsulation of anti‐BCR‐ABL siRNA and imatinib mesylate in transferrin receptor‐targeted sterically stabilized liposomes for chronic myeloid leukemia treatmentBiotechnology and Bioengineering, 2010
- TAT‐mediated intracellular protein delivery to primary brain cells is dependent on glycosaminoglycan expressionBiotechnology and Bioengineering, 2009